The involvement of epigenetic modifications such as promoter methylation is well known for a variety of established tumour suppressor genes, the most prominent examples being the retinoblastoma gene product and the cyclin-dependent kinase inhibitor CDKN2A. Here, CDKN3 is linked to neoplasm.